Company, Employee of: Eli Lilly and Company, Paul Emery Grant/research support from: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, Roche, Consultant for: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Gilead, Samsung, Sandoz and Lilly, Sreekumar Pillai Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Philip Helliwell Grant/research support from: Paid to charity: from AbbVie, Janssen and Novartis, Consultant for: Paid to charity: from AbbVie, Amgen, Pfizer, and UCB and Celgene. Paid to self: from Celgene and Galapagos

DOI: 10.1136/annrheumdis-2019-eular.8709

LB0006

SUBCUTANEOUS SECUKINUMAB 300MG AND 150MG PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS OVER 2 YEARS: RESULTS FROM THE PHASE 3 FUTURE-5 TRIAL

Philip J. Mease¹, Robert B.M. Landewé², Proton Rahman³, Hasan Tahir⁴, Atul Singhal⁵, Elke Boettcher⁶, Sandra Navarra⁷, Aimee Readie⁸, Shephard Mpofu⁹, Eumorphia Maria Delicha⁹, Luminita Pricop⁹, Désirée van der Heijde¹⁰. ¹Swedish Medical Centre and University of Washington, Seattle, United States of America; ²University of Amsterdam and Atrium Medical Centre, Amsterdam, Netherlands; ³Memorial University, Newfoundland and Labrador, Canada; ⁴Whipps Cross Hospital, London, United Kingdom; ⁵Southwest Rheumatology, Dallas, United States of America; ⁶Rheumazentrum Favoriten, Vienna, Austria; ⁷University of Santo Tomas Hospital, Manila, Philippines; ⁸Novartis Pharmaceuticals Corp., East Hanover, United States of America; ⁹Novartis Pharma AG, Basel, Switzerland; ¹⁰Leiden University Medical Centre, Leiden, Netherlands

Background: Secukinumab (SEC) provided sustained clinical efficacy, and inhibition of radiographic progression over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA) in the FUTURE 5 study¹.

Objectives: To report the effect of SEC on radiographic progression at Wk 104 (2 years) in PsA pts in the FUTURE 5 study.

Methods: Adults (N=996) with active PsA, stratified by prior anti-TNF therapy (naïve and inadequate response/intolerance [IR]) were randomised 2:2:2:3 to subcutaneous SEC 300mg with loading dose (LD; 300mg), 150mg LD (150mg), 150mg no LD, or placebo at baseline (BL), Wks 1, 2, 3, 4, and every 4 wks thereafter. Pts could have SEC dose escalated from 150 to 300 mg starting from Wk 52, based on physicians' judgement. Data are shown for pts originally randomised to SEC; 150mg groups include pts who had dose escalated to 300mg. Concomitant MTX (≤ 25 mg/week) was allowed. Radiographic progression (mean change in van der Heijde-modified total Sharp score [vdH-mTSS] and its components: erosion and joint space narrowing [JSN] scores, was based on hand/wrist/foot X-rays obtained at BL and Wk 104, and assessed by two blinded readers (plus an adjudicator if required). Other efficacy endpoints included ACR20/50, PASI90 and resolution of dactylitis and enthesitis.

Table. Summary of Efficacy Results

Mean change in vdH-mTSS scores from BL to Wk 104 (BL score)			
	300mg N=222 n=191	150mg group* N=220 n=181	150mg no LD group* N=222 n=169
vdH-mTSS	0.37 (12.07)	0.52 (11.47)	0.41 (13.99)
Erosion	0.27 (7.15)	0.27 (6.67)	0.38 (8.07)
JSN	0.11 (4.92)	0.24 (4.79)	0.03 (5.92)
Clinical responses at Wk 104 (% responders [n])			
	300 mg N = 222	150 mg group* N = 220	150 mg no LD group* N = 222
ACR20	77.0 (187)	79.4 (175)	78.0 (168)
ACR50	51.9 (187)	52.6 (175)	57.7 (168)
PASI90 ¹	70.1 (97)	59.2 (103)	62.6 (91)
Resolution of enthesitis ²	78.0 (118)	80.3 (117)	69.5 (95)
Resolution of dactylitis ³	82.8 (64)	85.5 (62)	89.3 (75)
Observed data			
* 150mg and 150mg no load arms include 86 and 92 pts, respectively, who were dose escalated at Wk 52 or later.			
N, number of pts randomised; n, number of pts with data at BL and Wk 104.			
Data from pts with: ¹ BL psoriasis $\geq 3\%$ body surface area, ² enthesitis at BL, ³ dactylitis at BL			

Results: Overall, 84.7% (300mg), 82.3% (150mg) and 75.2% (150mg no LD) pts completed 2 years of treatment. A total of 86 (39%) and 92 (41%) pts had their dose escalated to 300mg in the 150mg and 150mg no LD groups, respectively. Inhibition of radiographic progression was sustained with SEC through 2 years (Table 1). Proportions of pts with no radiographic progression (change from BL in mTSS ≤ 0.5) with SEC were 89.5% (300 mg), 82.3% (150 mg), and 81.1% (150 mg no LD) at 2 years; corresponding proportion of pts for change from BL in mTSS ≤ 0.0 were: 81.2%, 69.1% and 73.4%, respectively. Clinical responses were also sustained through 2 years (Table 1).

Conclusion: Subcutaneous secukinumab provided sustained inhibition of radiographic progression and sustained clinical responses through 2 years of treatment in pts with active PsA.

REFERENCE

[1] Mease PJ *et al. Arthritis Rheumatol* 2018;70(suppl 10).

Disclosure of Interests: Philip J Mease Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., and UCB., Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., and UCB., Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Leo, Merck, Novartis, Pfizer and UCB., Robert B.M. Landewé: None declared, Proton Rahman Grant/research support from: Investigator for Janssen Research & Development, LLC and Novartis, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, and Novartis, Hasan Tahir Grant/research support from: Novartis, Eli-Lilly, Speakers bureau: AbbVie, Janssen, Eli Lilly, and Novartis, Atul Singhal Grant/research support from: AAbbVie, Gilead, Sanofi, Regeneron, Amgen, Roche, BMS, Janssen, Lilly, Novartis, Pfizer, UCB, Astra Zeneca, MedImmune, Fujifilm, Nichi-Iko, Mallinckrodt, Speakers bureau: AbbVie, Elke Boettcher Consultant for: Amgen, Roche, Eli Lilly, Pfizer, MSD, Novartis, Speakers bureau: Amgen, Roche, Eli Lilly, Pfizer, MSD, Novartis, Sandra Navarra Speakers bureau: Astellas, Johnson & Johnson, Novartis, Pfizer, Aimee Readie Shareholder of: Novartis, Employee of: Novartis, Shephard Mpofu Shareholder of: Novartis, Employee of: Novartis, Eumorphia Maria Delicha Consultant for: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Désirée van der Heijde Consultant for: AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, Union Chimique Belge
DOI: 10.1136/annrheumdis-2019-eular.8808

LB0007

SUBCUTANEOUS TANEZUMAB FOR OSTEOARTHRITIS PAIN: A 24-WEEK PHASE 3 STUDY WITH A 24-WEEK FOLLOW UP

Francis Berenbaum¹, Francisco J. Blanco², Ali Guermazi³, Eric Vignon⁴, Kenji Miki⁵, Takaharu Yamabe⁶, Lars Viktrup⁷, Rod Junor⁸, William Carey⁸, Mark Brown⁶, Ken Verburg⁶, Christine West⁶. ¹Sorbonne Université, INSERM, AP-HP Hospital Saint Antoine, Paris, France; ²INIBIC-Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; ³Boston University School of Medicine, Boston, United States of America; ⁴Université Claude Bernard, Lyon, France; ⁵Osaka Yukioka College of Health Science, Hayaishi Hospital, Osaka, Japan; ⁶Pfizer Inc, Groton, United States of America; ⁷Eli Lilly & Company, Indianapolis, United States of America; ⁸Pfizer Ltd, Tadworth, United Kingdom

Background: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for treatment of osteoarthritis (OA) pain.

Objectives: To assess efficacy and safety of tanezumab in patients with moderate to severe OA pain who have not responded to or cannot tolerate standard of care analgesics.

Methods: A randomized, double-blind, placebo-controlled study (24 week treatment; 24 week follow-up) was conducted in patients in Europe and Japan with moderate to severe OA pain of the knee or hip and history of insufficient pain relief or intolerance to acetaminophen, oral nonsteroidal anti-inflammatory drug, and either tramadol or opioids (or unwilling to take opioids). Patients received subcutaneous tanezumab (2.5 or 5 mg) or placebo at baseline, week 8, and week 16. Co-primary endpoints were change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain, WOMAC Physical Function, and Patient Global Assessment of OA (PGA-OA) scores at week 24. Safety, including independent adjudication of joint safety events, was assessed.

Results: Tanezumab 5 mg met all co-primary endpoints (Fig. 1). Tanezumab 2.5 mg met WOMAC Pain and Physical Function endpoints but not the PGA-OA endpoint; thus, this dose did not meet pre-specified efficacy criteria. The occurrence